Posted on April 11, 2016
Researchers at the Institute for Biomedical Sciences at Georgia State University and Southwest University in China report that their work in the development of nanoparticles to reduce the expression of CD98, a glycoprotein that promotes inflammation, may point the way to a safe and effective treatment for inflammatory bowel disease (IBD). They further suggest that the development of nanotherapeutic strategies could be an alternative to currently available drugs, which are limited by serious side effects, in treating inflammatory conditions such as IBD. The findings are published in the journal Colloids and Surfaces B: Biointerfaces.
According to the Centers for Disease Control and Prevention, up to 1.3 million Americans suffer from IBD, which typically worsens over time and causes severe gastrointestinal symptoms, such as persistent diarrhea, cramping abdominal pain, fever, rectal bleeding, loss of appetite, and weight loss. IBD patients additionally are at increased risk for colon cancer. The research team reported that when introduced to microphages, the activated immune cells involved in IBD, the nanoparticles had an anti-inflammatory effect and no apparent toxicity.
Read more about IBD, here.
A news story about the study findings, with a link to the journal article, may be found here.